DUBLIN, April 11, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today unveiled Frames of Mind, an interactive campaign to promote awareness of the impact that migraine can have on patients' everyday lives. People living with this often debilitating condition are encouraged to submit original artwork depicting how the symptoms of migraine personally affect them.
An estimated 36 million Americans are living with migraine, a chronic disorder with episodic attacks that is characterized by an extremely disabling collection of neurological symptoms.1,2 Migraine attacks can cause significant pain for hours to days and can be so severe that the pain is disabling.3 In fact, the World Health Organization places migraine as one of the 10 most disabling medical illnesses on the planet, and Chronic Migraine, which is characterized by 15 or more headache days per month with headaches lasting four hours a day or longer and at least eight headache days associated with migraine, is even more incapacitating.1,4
"We are excited to collaborate with Allergan on this eye-opening campaign that we hope will unify the migraine community," said Dr. David Dodick, Chairman of the American Migraine Foundation. "While the symptoms of migraine can occur in a myriad of unique ways, we hope to underscore the common needs of this community and empower patients to better manage their condition, advocate for access to care and appropriate treatment options, and inspire funding for research into the causes and better treatments for migraine."
Migraine is a condition that is influenced by lifestyle and environmental factors. Along with the often debilitating throbbing pain, attacks can be accompanied by nausea, vomiting, and extreme sensitivity to light and sound.2 Starting today, people living with migraine are encouraged to create art submissions that visually depict how these various symptoms of migraine affect them both physically and emotionally. Digital, high resolution versions of the original works of art should then be submitted via email to FramesOfMind@toniclc.com, noting the artist's name, location, and contact information.
Select submissions chosen by notable migraine experts will be displayed at the 59th Annual Scientific Meeting of the American Headache Society from June 8 – June 11, 2017 at the Westin Boston Waterfront in Boston, MA and other migraine-related events throughout the remainder of 2017. Additionally, art submissions will be displayed on the My Chronic Migraine Facebook Page.
"Allergan is dedicated to supporting the millions of Americans living with the debilitating effects of migraine and educating the public about this condition in order to encourage proper diagnosis and treatment," said David Nicholson, Chief R&D Officer at Allergan. "In addition to our focus on advancing research and treatment options, we are committed to offering education and support that will make a true difference in the lives of this patient community."
Allergan, a leader in the Migraine space, is advancing its migraine program with two investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine. Allergan's CGRPs, ubrogepant in Phase III for the acute treatment of migraine and atogepant in Phase II for the prevention of migraine, are expected to be the first oral CGRP receptor antagonists to market.
Allergan's Commitment to People with Migraine
Allergan is committed to advancing the science of migraine through ongoing research and clinical investment, while providing innovative treatment approaches, educational opportunities, and support services that improve the lives of patients. Allergan tirelessly pursues freedom from migraine in partnership with the entire migraine community.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
1 Migraine Research Foundation. Migraine Facts. http://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed April 5, 2017.
2 Haut SR, Bigal ME, and Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol. 2006;5(2):148-157.
3 Mayo Clinic. Migraine. http://www.mayoclinic.org/diseases-conditions/migraine-headache/home/ovc-20202432. Accessed March 7, 2017.
4 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 3rd edition. Cephalalgia. 2013;33(9):629-808.
SOURCE Allergan plc